Vince O’Neill

978 total citations · 1 hit paper
17 papers, 744 citations indexed

About

Vince O’Neill is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Vince O’Neill has authored 17 papers receiving a total of 744 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Vince O’Neill's work include Peptidase Inhibition and Analysis (5 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Prostate Cancer Treatment and Research (3 papers). Vince O’Neill is often cited by papers focused on Peptidase Inhibition and Analysis (5 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Prostate Cancer Treatment and Research (3 papers). Vince O’Neill collaborates with scholars based in United States, United Kingdom and France. Vince O’Neill's co-authors include Johan Skog, Mikkel Noerholm, Stefan Bentink, Gordon Brown, Michael Donovan, Susan Belzer, John T. Wei, Michael W. Kattan, Gerald L. Andriole and Peter R. Carroll and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

Vince O’Neill

17 papers receiving 734 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy

2016 489 citations James M. McKiernan, Michael Donovan et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vince O’Neill United States	7	463	388	315	118	51	17	744
Pablo Reclusa Belgium	10	557 1.2×	470 1.2×	200 0.6×	173 1.5×	41 0.8×	15	762
A. Marije Hoogland Netherlands	13	408 0.9×	278 0.7×	347 1.1×	112 0.9×	35 0.7×	16	695
Mari Peltola Finland	11	377 0.8×	252 0.6×	593 1.9×	90 0.8×	65 1.3×	16	874
Sahar Al‐Haddad Canada	9	233 0.5×	243 0.6×	220 0.7×	216 1.8×	84 1.6×	14	609
Elena Castellanos-Rizaldos United States	11	529 1.1×	475 1.2×	144 0.5×	127 1.1×	19 0.4×	17	692
Lisa K. Spary United Kingdom	9	432 0.9×	302 0.8×	95 0.3×	174 1.5×	22 0.4×	13	630
Maria Maddalena Tumedei Italy	15	165 0.4×	213 0.5×	296 0.9×	286 2.4×	39 0.8×	46	632
S. Ménard Canada	7	368 0.8×	208 0.5×	285 0.9×	243 2.1×	57 1.1×	10	697
Davide Quaresmini Italy	11	265 0.6×	257 0.7×	119 0.4×	352 3.0×	51 1.0×	20	699

Countries citing papers authored by Vince O’Neill

Since Specialization

Citations

This map shows the geographic impact of Vince O’Neill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vince O’Neill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vince O’Neill more than expected).

Fields of papers citing papers by Vince O’Neill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vince O’Neill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vince O’Neill. The network helps show where Vince O’Neill may publish in the future.

Co-authorship network of co-authors of Vince O’Neill

This figure shows the co-authorship network connecting the top 25 collaborators of Vince O’Neill. A scholar is included among the top collaborators of Vince O’Neill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vince O’Neill. Vince O’Neill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Fitzgerald, Allison A., Shangzi Wang, Veena R. Agarwal, et al.. (2021). DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. Journal for ImmunoTherapy of Cancer. 9(11). e002837–e002837. 53 indexed citations

Monk, Paul, Jie Zhang, Dan Costin, et al.. (2021). 610P BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase II results. Annals of Oncology. 32. S651–S651. 4 indexed citations

Aggarwal, Rahul, Dan Costin, Jingsong Zhang, et al.. (2021). BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). 124–124. 4 indexed citations

Wang, Shangzi, Allison A. Fitzgerald, Louis M. Weiner, et al.. (2020). Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis. Cancer Research. 80(16_Supplement). 6636–6636. 2 indexed citations

Agarwal, Veena R., et al.. (2020). Abstract 962: The dipeptidyl peptidase inhibitor BXCL701 activates innate immunity followed by adaptive immunity on a molecular and cellular level in a mouse model of pancreatic cancer. Cancer Research. 80(16_Supplement). 962–962. 1 indexed citations

McKiernan, James M., Michael Donovan, Vince O’Neill, et al.. (2016). A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncology. 2(7). 882–882. 489 indexed citations breakdown →

Donovan, Michael, Stefan Bentink, Mikkel Noerholm, Vince O’Neill, & Johan Skog. (2016). Extended analysis of a validated urine-exosome signature to predict high grade prostate cancer on initial biopsy: Performance across multiple sub-groups.. Journal of Clinical Oncology. 34(2_suppl). 42–42. 1 indexed citations

McKiernan, James M., Michael Donovan, Vince O’Neill, et al.. (2015). PII-LBA2 VALIDATION OF A NOVEL NON-INVASIVE URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER IN PATIENTS UNDERGOING INITIAL BIOPSY WITH AN EQUIVOCAL PSA.. The Journal of Urology. 193(4S). 2 indexed citations

Donovan, Michael, Mikkel Noerholm, Stefan Bentink, et al.. (2015). A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer and Prostatic Diseases. 18(4). 370–375. 136 indexed citations

10.

Donovan, Michael, Mikkel Noerholm, Stefan Bentink, et al.. (2015). Interim performance of a non-DRE urine exosome gene signature to predict Gleason ≥7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial.. Journal of Clinical Oncology. 33(15_suppl). 5064–5064. 2 indexed citations

11.

Krug, Anne K., Chris Karlovich, Tina Koestler, et al.. (2015). Abstract B136: Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs. Molecular Cancer Therapeutics. 14(12_Supplement_2). B136–B136. 11 indexed citations

12.

Donovan, M. J., James A. Eastham, James M. McKiernan, et al.. (2015). 2576 A non-invasive urine exosome gene expression assay (Exo106) accurately predicts pathologic stage and grade in the prostatectomy specimen. European Journal of Cancer. 51. S503–S503. 1 indexed citations

13.

Hurley, James, Lujun Hu, Graham Brock, et al.. (2015). 452 Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma. European Journal of Cancer. 51. S96–S96. 1 indexed citations

14.

Donovan, Michael, Mikkel Noerholm, Stefan Bentink, et al.. (2015). A first catch, non-DRE urine exosome gene signature to predict Gleason 7 prostate cancer on an initial prostate needle biopsy.. Journal of Clinical Oncology. 33(7_suppl). 45–45. 3 indexed citations

15.

Thompson, Dawn, K. T. Flaherty, W. Messersmith, et al.. (2009). A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma. Journal of Clinical Oncology. 27(15_suppl). e14584–e14584. 13 indexed citations

16.

Hirsch, Fred R., Marileila Varella‐Garcia, Paul A. Bunn, et al.. (2007). Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC. Journal of Clinical Oncology. 25(18_suppl). 7570–7570. 11 indexed citations

17.

Herbst, Roy S., Vince O’Neill, Louis Fehrenbacher, et al.. (2006). 53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. European Journal of Cancer Supplements. 4(12). 20–20. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact